Similarly, the phase III PAPILLON trial showed the superiority of amivantamab with chemotherapy over chemotherapy alone as the first-line treatment for advanced NSCLC with EGFR exon20ins. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.